ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 24, 2016--
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company
with a focus on pluripotent stem cell technologies, today announced that
it will release third quarter financial and operating results on
Thursday, November 3, 2016, after the close of the U.S. financial
markets. The Company will host a conference call and webcast on
Thursday, November 3, 2016, at 4:30 p.m. Eastern Time / 1:30 p.m.
Pacific Time to discuss the results and recent corporate developments.
The conference call dial-in number in the U.S./Canada is 1-(877)
407-0784. For international participants outside the U.S./Canada, the
dial-in number is (201) 689-8560. For all callers, please refer to the
“BioTime, Inc. Conference Call.” The live webcast can be accessed on the
“Events & Presentations” page of the “Investors & Media” section on the
company’s website at http://www.biotimeinc.com/.
A replay of the conference call will be available for seven business
days beginning about two hours after the conclusion of the live call, by
calling toll-free from U.S./Canada: 1-844-512-2921; international
callers dial 1-412-317-6671. Use the Conference ID 13648138.
Additionally, the archived webcast will be available on the “Events &
Presentations” page of the “Investors & Media” section on the company’s
website at http://www.biotimeinc.com/.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
Company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products.
In addition to the development of therapeutics, BioTime’s research and
other activities have resulted, over time, in the creation of other
subsidiaries that address other non-therapeutic market opportunities
such as cancer diagnostics, drug development and cell research products,
and mobile health software applications.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005496/en/
Source: BioTime, Inc.
EVC Group, Inc.
Gotham Communications, LLC